The 2021 Society of Thoracic Surgeons (STS), Society of Cardiovascular Anesthesiologists (SCA), American Society of Extracorporeal Technology (AmSECT), and Society for the Advancement of Blood Management (SABM) update to the clinical practice guidelines on patient blood management recommends goal-directed transfusion algorithms incorporating point-of-care (POC) testing, including viscoelastic testing, to reduce periprocedural bleeding and transfusion in cardiac surgical patients (Class I, Level B-R). The guideline notes that POC-based viscoelastic testing algorithms have demonstrated reductions in allogeneic blood product transfusions in high-risk cardiovascular surgery patients. In a large prospective multicenter study involving more than 7,000 cardiac surgery patients, implementation of a viscoelastic testing-based transfusion algorithm in combination with platelet function testing significantly reduced red blood cell and platelet transfusions compared with preimplementation practice. Additionally, several studies incorporating viscoelastic-guided transfusion algorithms have substituted early administration of prohemostatic factor concentrates, including prothrombin complex concentrates (PCCs) and fibrinogen concentrate, for allogeneic blood products, resulting in reduced transfusion requirements. However, the guideline emphasizes that the safety of this approach requires careful evaluation and monitoring of hemostasis. [1]
Meta-analyses and systematic reviews also indicate that POC viscoelastic testing-guided management reduces bleeding and transfusion rates, although a demonstrable reduction in morbidity has not been established. The guideline further notes that viscoelastic testing has been associated with decreased healthcare costs through reductions in transfusion requirements and associated transfusion risks. However, these findings reflect multimodal, goal-directed transfusion strategies rather than the independent effect of fibrinogen concentrate administration. The guideline does not identify Fibryga specifically, provide comparative data between fibrinogen concentrate and cryoprecipitate or other fibrinogen concentrate products, or establish differences in fibrinogen utilization or dosing, total factor product utilization, direct product costs or cost savings, hospital length of stay, operating room time, or specific bleeding outcomes attributable to fibrinogen concentrate. Accordingly, the evidence supports incorporating fibrinogen concentrate into appropriately monitored, viscoelastic-guided blood management protocols as a potential alternative to allogeneic blood products, but does not establish the comparative clinical or economic benefits of Fibryga over cryoprecipitate or other fibrinogen concentrates. [1]
The 2024 European Association for Cardio-Thoracic Surgery (EACTS) and European Association of Cardiothoracic Anaesthesiology and Intensive Care (EACTAIC) guidelines on patient blood management in adult cardiac surgery emphasize fibrinogen supplementation as an important hemostatic intervention in patients experiencing bleeding after cardiac surgery. Endogenous plasma fibrinogen is among the first coagulation factors depleted during significant bleeding and hemodilution, and observational studies have associated lower pre- and postoperative fibrinogen levels with increased bleeding risk. A 2018 meta-analysis of 8 randomized controlled trials (RCTs; N=597) found that fibrinogen concentrate reduced the proportion of patients requiring packed red blood cell (PRBC) transfusions (relative risk [RR] 0.64; 95% confidence interval [CI] 0.49 to 0.83), but did not significantly reduce overall exposure to allogeneic blood products, including PRBCs, platelets, and fresh frozen plasma (FFP; RR 0.79; 95% CI 0.53 to 1.18). Among the included trials, 3 studies (n=128) evaluated preoperative administration of 1–2 g of fibrinogen concentrate, with none demonstrating reduced allogeneic transfusion requirements. Five studies evaluated intraoperative administration of 2-8 g; one compared fibrinogen concentrate with platelet transfusion, while 2 studies (n= 167) using dosing guided by rotational thromboelastometry (ROTEM) or plasma fibrinogen levels reported reductions in allogeneic blood product requirements. However, 2 other RCTs (n= 272) involving patients with bleeding after complex cardiac surgery found no significant benefit in bleeding volume or blood product transfusion requirements. A post hoc analysis further found that increasing fibrinogen levels beyond 2.87 g/L or maximum clot firmness of 14 mm on FIBTEM did not provide additional reductions in bleeding. The meta-analysis did not demonstrate reductions in mortality, reoperation, stroke, myocardial infarction, or thromboembolic events, although the small number of adverse events limited conclusions regarding safety. [2]
Regarding comparisons with cryoprecipitate, a large RCT involving 735 patients with clinically significant bleeding and hypofibrinogenemia following cardiac surgery found that 4 g of fibrinogen concentrate was non-inferior to 10 units of cryoprecipitate in terms of the number of blood components transfused within 24 hours postoperatively, suggesting comparable efficacy for reducing subsequent transfusion requirements (see Table 1). The guidelines therefore support considering fibrinogen supplementation in patients with persistent microvascular bleeding and confirmed hypofibrinogenemia (fibrinogen level <1.5 g/L or an equivalent viscoelastic testing result) to reduce postoperative bleeding and transfusion requirements (Class IIa, Level B). Routine prophylactic fibrinogen administration is not recommended (Class III, Level A). Although these findings support fibrinogen concentrate as an alternative to cryoprecipitate for targeted treatment of acquired hypofibrinogenemia, the guidelines do not identify Fibryga specifically or establish differences between individual fibrinogen concentrate formulations. Additionally, comparative data demonstrating reductions in total coagulation factor utilization, product costs, hospital length of stay (LOS), or operating room time with fibrinogen concentrate versus cryoprecipitate or other fibrinogen concentrates are not provided. Importantly, the comparative cryoprecipitate trial evaluated postoperative transfusion requirements rather than intraoperative outcomes during cardiac surgery, and its findings should not be interpreted as establishing the superiority of fibrinogen concentrate for intraoperative bleeding management. [2]
A 2025 systematic review and meta-analysis evaluated fibrinogen concentrate versus cryoprecipitate for acquired hypofibrinogenemia in cardiac surgery, including 4 RCTs with 945 participants (823 adults and 122 children). Three fibrinogen concentrate products were evaluated: Fibryga (2 RCTs), RiaSTAP (1 RCT), and Haemocomplettan P (1 RCT). Across the pooled studies, fibrinogen concentrate was not associated with significant differences compared with cryoprecipitate in postoperative mortality (RR 1.25; 95% CI 0.79 to 1.96), blood loss (standardized mean difference [SMD] -0.14; 95% CI -0.46 to 0.18), or transfusion rates of red blood cells (RR 0.98; 95% CI 0.77 to 1.26), platelets (RR 0.17; 95% CI 0.02 to 1.40), fresh frozen plasma (RR 0.48; 95% CI 0.16 to 1.45), or cryoprecipitate (RR 1.02; 95% CI 0.58 to 1.81). No significant differences were identified in infection, volume overload, transfusion reactions, or postoperative thrombosis, and no allergic reactions were reported. Exploratory analyses also found no significant differences in duration of mechanical ventilation, intensive care unit stay, or hospitalization. However, these findings reflect pooled results across different fibrinogen concentrates and do not establish Fibryga-specific comparative effectiveness. Additionally, the analysis did not discuss differences in intraoperative factor utilization, cost savings, or operating room time. Overall, the evidence suggests comparable clinical outcomes between fibrinogen concentrate and cryoprecipitate for correcting hypofibrinogenemia in cardiac surgery, but certainty was moderate for mortality and low for other outcomes; pediatric findings were particularly limited by small sample sizes and substantial heterogeneity. [3]